Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of JNJ-67670187 in healthy volunteers with optional antibiotic and laxative pretreatment
NL-OMON47984Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2018
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VE202 in inflammatory bowel disease (IBD) and autoimmune colitis (9 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and tolerability after single oral dose and Safety and tolerability after multiple oral doses with and without bowel preparation pretreatments. Started Dec 2018; status: active, not recruiting.
02
Drugs
VE202
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitis
Beyond the preview
Go deeper on NL-OMON47984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47984.